Compare · SIBN vs WST
SIBN vs WST
Side-by-side comparison of SI-BONE Inc. (SIBN) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SIBN and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $25.27B, about 33.7x SIBN ($749.9M).
- Over the past year, SIBN is down 0.1% and WST is up 61.9% - WST leads by 62.0 points.
- WST has been more active in the news (5 items in the past 4 weeks vs 3 for SIBN).
- WST has more recent analyst coverage (18 ratings vs 11 for SIBN).
- Company
- SI-BONE Inc.
- West Pharmaceutical Services Inc.
- Price
- $16.92-5.29%
- $358.22-0.42%
- Market cap
- $749.9M
- $25.27B
- 1M return
- +11.46%
- +8.40%
- 1Y return
- -0.12%
- +61.91%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 3
- 5
- Recent ratings
- 11
- 18
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest SIBN
- ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
- SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $52,375 worth of shares (3,134 units at $16.71), decreasing direct ownership by 1% to 277,375 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Maheshwari Anshul sold $55,627 worth of shares (3,317 units at $16.77), decreasing direct ownership by 1% to 256,560 units (SEC Form 4) to cover withholding tax
- Director Hilleman Jeryl L was granted 10,957 shares, increasing direct ownership by 33% to 43,772 units (SEC Form 4)
- Director Dunn Jeffrey W was granted 10,957 shares and sold $54,505 worth of shares (3,575 units at $15.25), increasing direct ownership by 75% to 16,057 units (SEC Form 4) to cover withholding tax
- Director Nishimura Mika was granted 10,957 shares, increasing direct ownership by 33% to 43,673 units (SEC Form 4)
- Director West Thomas A. was granted 10,957 shares, increasing direct ownership by 41% to 37,947 units (SEC Form 4)
- Director Freund John Gordon was granted 10,957 shares, increasing direct ownership by 25% to 54,258 units (SEC Form 4)
- Director Davis Timothy E Jr was granted 10,957 shares, increasing direct ownership by 17% to 76,679 units (SEC Form 4)
- SI-BONE Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits